Innovative Research & Development

Teva has been engaged in innovative research and development for over two decades now. During this period, it has made significant progress, mainly in two therapeutic fields: central nervous system (CNS ) and autoimmune (AI) diseases. Oncology is recently emerging as a potential new area (see Table). These efforts culminated in 2 innovative products introduction into global markets : Copaxone® ( glatiramer acetate) for MS and Azilect® for Parkinson's disease (PD). 

Most of the current pipe-line projects are based on research performed in the leading research institutes and start-up companies in Israel. With the acquisition of Ivax at the beginning of 2006, Teva's Innovative pipe-line has been enriched with several new molecules in clinical and pre-clinical stages of development. Attempts have been recently initiated towards licensing-in of promising products from additional sources.  

Multiple Sclerosis Franchise

Product

Indication

Status

Copaxone® 
(glatiramer acetate for Injection)

Relapsing-Remitting MS (R-R MS)

Approved world-wide. Phase IIIb/IV studies on-going, including a study in CIS patients , a study with a daily 40mg dose and various combination/induction protocols

Laquinimod

Relapsing MS

Phase III

Various other programs

 

Research

 

Other Neurological/Neurodegenerative Diseases 

Product

Indication

Status

Azilect® 
(rasagiline mesylate)

Parkinson's disease

Approved world-wide as a symptomatic treatment for both early patients, as monotherapy, and advanced patients, as adjuncive treatment to levodopa. A Phase IIIb to show effect on disease progression is on-going

Glatiramer acetate

ALS

Phase II

Rasagiline mesylate

Alzheimer's disease

Phase II

Talampanel

ALS

Phase II

Various other programs

 

Research

 

Auto-Immune/Inflammatory Diseases 

Product

Indication

Status

Edratide

Lupus

Phase II in SLE

TV-3813

Psoriasis

Pre-clinical

Various other programs

 

Research

Oncology 

Product

Indication

Status

Stem Ex® (with Gamida-Cell)

Hemato-oncological indications

Phase III

Talampanel

Glioma

Phase II

Various other programs

 

Research